Earnings Releases·Nov 4, 2026, 7:00 AM ET

Odyssey Therapeutics — Third Quarter 2026 Earnings Summary

Cash, cash equivalents, and marketable securities totaled $387 million as of September 30, 2026, providing funding runway into the second half of 2028.
Net loss widened to $53.1 million for the quarter ended September 30, 2026, compared to $35.5 million in the same period in 2025, driven by a 60% increase in R&D expenses to $42.1 million.
Clinical progress includes strengthened proof of concept for OD-001 in ulcerative colitis and completion of IND-enabling studies for OD-002, with top-line results for OD-001 trials and OD-002 healthy participant data expected in the second half of 2027.
Management announced the appointment of Anthony Opipari, M.D., Ph.D., as chief medical officer and Laura Hare as chief people officer to support the execution of the clinical development strategy.